Results 211 to 220 of about 29,006,367 (387)

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

open access: yesMolecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert   +13 more
wiley   +1 more source

Is a 100% renewable European power system feasible by 2050?

open access: yesApplied Energy, 2019
W. Zappa, M. Junginger, M. van den Broek
semanticscholar   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Don't Stop Me Now, `Cause I'm Having a Good Time Screening: Evaluation of Stopping Methods for Safe Use of Priority Screening in Systematic Reviews. [PDF]

open access: yesCochrane Evid Synth Methods
Repke T   +7 more
europepmc   +1 more source

Tolerability of desvenlafaxine 100 mg in women with vasomotor symptoms (VMS) associated with menopause: a pooled analysis of 5 trials [PDF]

open access: bronze, 2011
David F. Archer   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy